Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
PerkinElmer $800 million notes offering
We advised the joint bookrunners on the investment-grade debt offering
Bristol Myers Squibb debt tender offer
We advised the dealer managers on a debt tender offer
Heska $175 million follow-on offering
We advised the joint book-running managers and underwriters on the equity offering
Cigna $4.3 billion senior notes offering
We advised the underwriters on the investment-grade debt offering
InflaRx $75 million follow-on offering
We advised the underwriters on the equity offering
Adamas Pharmaceuticals $59 million stock offering
We advised the joint book-running managers on the SEC-registered equity offering
AVITA Medical $69.1 million follow-on offering
We advised the underwriters on the equity offering
I-Mab $177 million follow-on secondary offering of ADSs
We advised the underwriters on the equity offering
Evernorth acquisition of MDLIVE
We are advising MDLIVE on the transaction
JOINN Laboratories HK$6.5 billion IPO
We advised JOINN Laboratories on its IPO and HKEX listing.